// App-Quantinova.ai

TPS623 : A phase 2, multicenter, open-label study evaluating trastuzumab deruxtecan (T-DXd) for the treatment of select human epidermal growth factor receptor 2 (HER2)-expressing solid tumors (DESTINY-PanTumor02).

Researchers

Presenter

  • Funda Meric-Bernstam

Principal Investigators

  • Chiedozie Anoka

  • Anna Dobrowolska

  • Anubhavini Chaudhry

  • Jacqui Rowbottom

  • Mark Gustavson

  • Soham D. Puvvada

Medical Centers

  • Department of Investigational Cancer Therapeutics (Phase 1 Program), The University of Texas MD Anderson Cancer Center, Houston, TX

  • AstraZeneca Pharmaceuticals, Gaithersburg, MD

  • AstraZeneca Pharma Poland Sp. z oo, Warsaw, Poland

  • AstraZeneca Pharmaceuticals, Cambridge, United Kingdom

Locations

  • United States

  • Poland

  • United Kingdom

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Non Small Cell Lung cancer

  • Solid malignancies

  • Lung Cancer

Biomarkers

  • N/A

Drug/Treatment

  • Trastuzumab

Outcome

  • N/A

Study Design

  • Pharmacokinetics

  • Open Label

  • Multicenteric

Phase

  • II

Study Id's

  • NCT04482309

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved